|
Jun 25
|
Novartis completes acquisition of Regulus Therapeutics
|
|
Jun 25
|
Novartis announces expiration of Regulus Therapeutics tender offer
|
|
Jun 24
|
Novartis AG (NVS): A Bull Case Theory
|
|
Jun 24
|
Top Analyst Reports for JPMorgan, Novartis & AT&T
|
|
Jun 24
|
Brain Cancer Market Research Report 2025-2035 | Growing Shifts Toward Targeted Therapies and Immunotherapy Over Traditional Methods
|
|
Jun 24
|
Gene and Cell Therapies Targeting CNS Disorders Market Research 2025-2035 | Technological Advancements in Precision Delivery Drive Growth, High Costs Challenging Accessibility
|
|
Jun 23
|
Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer
|
|
Jun 20
|
Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.
|
|
Jun 20
|
Novartis’ ribociclib approved in Canada for early breast cancer
|
|
Jun 20
|
NYSE Content Advisory: Pre-Market update + Wall Street reopens after Juneteenth
|
|
Jun 19
|
FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention
|
|
Jun 19
|
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?
|
|
Jun 17
|
Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data
|
|
Jun 17
|
Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer
|
|
Jun 16
|
RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development
|
|
Jun 16
|
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
|
|
Jun 16
|
Buy These 5 Low-Leverage Stocks Amid Fresh Iran-Israel War
|
|
Jun 15
|
Berenberg Bank Maintains a Hold Rating on Novartis (NVS)
|
|
Jun 13
|
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
|
|
Jun 13
|
Novartis reports positive results from Phase IIIB study of iptacopan for PNH
|